Neurocognitive and hypokinetic movement disorder with features of parkinsonism after BCMA-targeting CAR-T cell therapy

O Van Oekelen, A Aleman, B Upadhyaya… - Nature medicine, 2021 - nature.com
B-cell maturation antigen (BCMA) is a prominent tumor-associated target for chimeric
antigen receptor (CAR)-T cell therapy in multiple myeloma (MM). Here, we describe the case …
被引用次数：130 相关文章

Neurocognitive and hypokinetic movement disorder with features of parkinsonism after BCMA-targeting CAR-T cell therapy

O Van Oekelen, A Aleman, B Upadhyaya… - Nature …, 2021 - pubmed.ncbi.nlm.nih.gov
B-cell maturation antigen (BCMA) is a prominent tumor-associated target for chimeric
antigen receptor (CAR)-T cell therapy in multiple myeloma (MM). Here, we describe the case …
[HTML] nih.gov

[HTML][HTML] Neurocognitive and hypokinetic movement disorder with features of parkinsonism following BCMA-targeting CAR-T cell therapy

O Van Oekelen, A Aleman, B Upadhyaya… - Nature …, 2021 - ncbi.nlm.nih.gov
Neurocognitive and hypokinetic movement disorder with features of parkinsonism following
BCMA-targeting CAR-T cell therapy - PMC Back to Top Skip to main content NIH NLM Logo …

Neurocognitive and hypokinetic movement disorder with features of parkinsonism after BCMA-targeting CAR-T cell therapy.

O Van Oekelen, A Aleman, B Upadhyaya… - Nature …, 2021 - europepmc.org
B-cell maturation antigen (BCMA) is a prominent tumor-associated target for chimeric
antigen receptor (CAR)-T cell therapy in multiple myeloma (MM). We describe the case of a …

Neurocognitive and hypokinetic movement disorder with features of parkinsonism after BCMA-targeting CAR-T cell therapy

O Van Oekelen, A Aleman, B Upadhyaya… - paper.sciencenet.cn
B-cell maturation antigen (BCMA) is a prominent tumor-associated target for chimeric
antigen receptor (CAR)-T cell therapy in multiple myeloma (MM). Here, we describe the case …